|Bid||156.58 x 300|
|Ask||156.64 x 100|
|Day's Range||154.91 - 158.34|
|52 Week Range||139.36 - 209.22|
|PE Ratio (TTM)||69.65|
|Dividend & Yield||0.92 (0.58%)|
|1y Target Est||N/A|
Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.
Shire was the seventh-largest holding in Cooperman's Omega Advisors’ portfolio in 2Q17, representing nearly 3.5% of total holdings.
Top Research Reports for Disney, Kraft Heinz & CVS Health